Protocol Ledger

NCT07043400 · Phase III · RECRUITING

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Interventional Phase III clinical trial protocol NCT07043400 sponsored by BeiGene in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-08-27 Enrollment: 351 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07043400
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)351 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07043400
Protocol FieldVerified Registry Value
NCT IdentifierNCT07043400
Consolidated Lead SponsorBeiGene
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment351 participants (ESTIMATED)
Registered Start Date2025-08-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07043400
Hospital Research SiteLocationSite Profile
Cancer and Blood Specialty ClinicLos Alamitos, CAOpen Hospital Dossier ->
Northwestern Memorial and Lurie Cancer CenterChicago, ILOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI